Terns Pharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €25.49M +14.5% -€105.39M -16.2% -413.4% +1.5 pp N/A N/A
    (estimated) €22.26M +350.6% -€125.77M -0.8% -565.0% +20 pp N/A N/A
    (estimated) €4.94M +501.0% -€126.78M +16.0% -2,566.6% +110 pp N/A N/A
    (estimated) €821.85K +∞% -€109.31M +22.0% -13,300.0% -130 pp N/A N/A
    (estimated) €0.00 +NaN% -€89.60M +17.8% N/A N/A N/A
    €0.00 +NaN% -€76.07M -1.5% N/A -€59.90M +3.9% N/A
    €0.00 +NaN% -€77.23M +49.5% N/A -€57.65M +37.9% N/A
    €0.00 -100.0% -€51.66M +20.3% N/A -€41.81M +17.7% N/A
    €856.09K +∞% -€42.94M +23.6% -5,015.8% -50 pp -€35.52M +42.0% -4,148.7% -41 pp
    €0.00 +NaN% -€34.73M -41.0% N/A -€25.02M -55.3% N/A
    €0.00 +NaN% -€58.92M +288.6% N/A -€55.92M +266.4% N/A
    €0.00 -€15.16M N/A -€15.26M N/A

    Notifications